Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 3/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PNP | P00491 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5491579 | 0.89 | TLR8 (0.44) | TLR8NOS2 | |
| SCHEMBL356158 | 0.88 | TLR8 (0.45) | TLR8 | |
| SCHEMBL20137346 | 0.87 | ATAD2 (0.34) | BACE1 | |
| SCHEMBL20165 | 0.86 | DHFR (0.33) | DHFRPNP | |
| SCHEMBL542389 | 0.81 | PNP (0.37) | PNP | |
| SCHEMBL7597747 | 0.80 | MPO (0.38) | TLR8 | |
| SCHEMBL7607407 | 0.79 | MPO (0.40) | TLR8 | |
| SCHEMBL1665906 | 0.79 | PNP (0.31) | PNP | |
| SCHEMBL7602254 | 0.77 | MPO (0.40) | TLR8 | |
| SCHEMBL7601001 | 0.77 | HPGD (0.47) | DHFRPNP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 620 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150211004-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| EP-0980379-B1 | CHIMERIC OLIGONUCLEOTIDES AND THE USE THEREOF | MAX DELBRUECK CENTRUM (DE) | 2002-08-07 | — | — | EP | claimed |
| US-20010039263-A1 | Chimeric oligonucleotides and the use thereof | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN | 2001-11-08 | — | — | US | claimed |
| EP-0980379-A2 | CHIMERIC OLIGONUCLEOTIDES AND THE USE THEREOF | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2000-02-23 | — | — | EP | claimed |
| WO-1998050397-A2 | CHIMERIC OLIGONUCLEOTIDES AND THE USE THEREOF | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 1998-11-12 | — | — | WO | claimed |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CARIS SCIENCE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | UNIV ARIZONA STATE (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONE STATE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | TRIBUNE THERAPEUTICS AB (SE) | 2026-02-12 | — | — | US | disclosed |
| EP-4683716-A1 | DNA NANODEVICES FOR SPECIFIC AND EFFICIENT DELIVERY OF FUNCTIONAL PAYLOADS TO THE CYTOPLASM AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4680212-A1 | ADAR1 INHIBITORS FOR TREATING CANCER | Institute of Cancer Research Royal Cancer Hospital (GB) | 2026-01-21 | — | — | EP | disclosed |
| EP-0980379-A2 | CHIMERIC OLIGONUCLEOTIDES AND THE USE THEREOF | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998050397-A2 | CHIMERIC OLIGONUCLEOTIDES AND THE USE THEREOF | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 1998-11-12 | — | — | WO | disclosed |
| US-5756291-A | IDENTIFYING OLIGOMER SEQUENCES; QUALITATIVE ANALYSIS; ANALYSIS OF THROMBIN BY COMPLEXING | GILEAD SCIENCES, INC. (US) | 1998-05-26 | — | — | US | disclosed |
| WO-1996008559-A1 | GLYCOSAMINOGLYCAN-DEGRADING ENZYME INHIBITION AND RESULTANT DISEASE THERAPIES | CARDIAC CRC NOMINEES PTY. LTD. (AU) | 1996-03-21 | — | — | WO | disclosed |
| EP-0572529-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992014843-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | DDX41, DDX5, DDX6 | BACE1 4526/4885DHFR 1953/4885EPHX2 2147/4885 |
| US-20010039263-A1 | Chimeric oligonucleotides and the use thereof | RNGTT, TERT, DCLRE1B | BACE1 2844/4885DHFR 243/4885EPHX2 2173/4885 |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CD63, FLT4, NCL | BACE1 2020/4885DHFR 3737/4885EPHX2 4134/4885 |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | PKD2, CCNK, PKD1 | BACE1 2855/4885DHFR 4266/4885EPHX2 4099/4885 |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | PDCD1, TIA1, NSUN2 | BACE1 247/4885DHFR 1523/4885EPHX2 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.